Relationship of hospital-associated bleeding with length of stay and total hospitalization costs in patients hospitalized for atrial fibrillation

被引:4
作者
Amin, Alpesh N. [1 ]
Robinson, Scott B. [2 ]
Bowdy, Bruce D. [2 ]
Jing, Yonghua [3 ]
Johnson, Bernadette H. [2 ]
Wiederkehr, Daniel P. [4 ]
机构
[1] Univ Calif Irvine, Irvine, CA 92868 USA
[2] Premier Res Serv, Charlotte, NC USA
[3] Abbvie, Chicago, IL USA
[4] Pfizer, New York, NY USA
关键词
Non-valvular atrial fibrillation; Hospital associated bleed; Length of stay; Total hospitalization cost; PERCUTANEOUS CORONARY INTERVENTION; ORAL ANTICOAGULATION; STROKE PREVENTION; RISK-FACTORS; WARFARIN; THERAPY; POPULATION; ASPIRIN; EVENTS; IMPACT;
D O I
10.3111/13696998.2015.1134545
中图分类号
F [经济];
学科分类号
02 ;
摘要
Background:While literature has focused on the impact of bleeding beginning outside the hospital setting among patients with atrial fibrillation (AF), there is little information regarding bleeding that first occurs within a hospital setting. This study was performed to determine the association between hospital-associated bleeding in patients admitted for AF on outcomes of length of stay (LOS) and total hospitalization cost.Methods and results:The Premier research database was queried to identify adult inpatients discharged between 2008-2011 having a primary diagnosis code for AF where a bleeding diagnosis code was not present on admission. Regression was used to adjust for baseline differences in patients to estimate outcomes comparing patients with and without a hospital-associated bleed. There were 143,287 patients that met the study criteria. There were 2991 (2.1%) patients identified with a hospital associated bleed. After adjustment for covariates, the mean estimated LOS was significantly greater in the bleed group, at 6.0 days (95% CI=5.8-6.1) vs the no bleed group at 3.3 days (95% CI=3.3-3.3) (p<0.0001). Similarly, the adjusted mean estimated total hospitalization cost was also significantly greater in the bleed group, $12,069 (95% CI=$11,779-$12,366) vs $6561 (95% CI=$6538-$6583) in the no bleed group (p<0.0001).Conclusions:After adjustments for baseline differences the data show that the 2.1% (n=2991) of patients with hospital associated bleeding accounted for an estimated additional 8106 hospitalization days and $16.4 million dollars in cost over the study period compared to non-bleeders.
引用
收藏
页码:490 / 496
页数:7
相关论文
共 25 条
[11]   Comparative Validation of a Novel Risk Score for Predicting Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation The HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) Score [J].
Lip, Gregory Y. H. ;
Frison, Lars ;
Halperin, Jonathan L. ;
Lane, Deirdre A. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 57 (02) :173-180
[12]   Lifetime risk for development of atrial fibrillation - The Framingham Heart Study [J].
Lloyd-Jones, DM ;
Wang, TJ ;
Leip, EP ;
Larson, MG ;
Levy, D ;
Vasan, RS ;
D'Agostino, RB ;
Massaro, JM ;
Beiser, A ;
Wolf, PA ;
Benjamin, EJ .
CIRCULATION, 2004, 110 (09) :1042-1046
[13]   Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial [J].
Mant, Jonathan ;
Hobbs, F. D. Richard ;
Fletcher, Kate ;
Roalfe, Andrea ;
Fitzmaurice, David ;
Lip, Gregory Y. H. ;
Murray, Ellen .
LANCET, 2007, 370 (9586) :493-503
[14]   Bleeding in Patients Undergoing Percutaneous Coronary Intervention The Development of a Clinical Risk Algorithm From the National Cardiovascular Data Registry [J].
Mehta, Sameer K. ;
Frutkin, Andrew D. ;
Lindsey, Jason B. ;
House, John A. ;
Spertus, John A. ;
Rao, Sunil V. ;
Ou, Fang-Shu ;
Roe, Matthew T. ;
Peterson, Eric D. ;
Marso, Steven P. .
CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 2009, 2 (03) :222-U107
[15]   Quality of individual INR control and the risk of stroke and bleeding events in atrial fibrillation patients: A nested case control analysis of the ACTIVE W study [J].
Nieuwlaat, Robby ;
Connolly, Benjamin J. ;
Hubers, Lowiek M. ;
Cuddy, Spencer M. ;
Eikelboom, John W. ;
Yusuf, Salim ;
Connolly, Stuart J. .
THROMBOSIS RESEARCH, 2012, 129 (06) :715-719
[16]   Bleeding Risk During Oral Anticoagulation in Atrial Fibrillation Patients Older Than 80 Years [J].
Poli, Daniela ;
Antonucci, Emilia ;
Grifoni, Elisa ;
Abbate, Rosanna ;
Gensini, Gian Franco ;
Prisco, Domenico .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 54 (11) :999-1002
[17]  
Psaty BM, 1997, CIRCULATION, V96, P2455
[18]  
Rao SV, 2010, REV ESP CARDIOL, V63, P1
[19]   Should We Recommend Oral Anticoagulation Therapy in Patients With Atrial Fibrillation Undergoing Coronary Artery Stenting With a High HAS-BLED Bleeding Risk Score? [J].
Ruiz-Nodar, Juan M. ;
Marin, Francisco ;
Roldan, Vanessa ;
Valencia, Jose ;
Manzano-Fernandez, Sergio ;
Caballero, Luis ;
Hurtado, Jose A. ;
Sogorb, Francisco ;
Valdes, Mariano ;
Lip, Gregory Y. H. .
CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 2012, 5 (04) :459-466
[20]  
Steiner C, 2012, 201202 HCUP US AG HE